FibroGen Inc FGEN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:57 PM EDT
1.15quote price arrow up+0.01 (+0.88%)
Volume
19,332
Close
1.14quote price arrow up+0.01 (+0.88%)
Volume
758,637
52 week range
0.33 - 19.47
Loading...
  • Open1.12
  • Day High1.22
  • Day Low1.11
  • Prev Close1.13
  • 52 Week High19.47
  • 52 Week High Date06/05/23
  • 52 Week Low0.33
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap113.401M
  • Shares Out99.47M
  • 10 Day Average Volume1.19M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change28.62

KEY STATS

  • Open1.12
  • Day High1.22
  • Day Low1.11
  • Prev Close1.13
  • 52 Week High19.47
  • 52 Week High Date06/05/23
  • 52 Week Low0.33
  • 52 Week Low Date11/10/23
  • Market Cap113.401M
  • Shares Out99.47M
  • 10 Day Average Volume1.19M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change28.62

RATIOS/PROFITABILITY

  • EPS (TTM)-2.93
  • P/E (TTM)-0.39
  • Fwd P/E (NTM)-0.78
  • EBITDA (TTM)-259.28M
  • ROE (TTM)-42,790.17%
  • Revenue (TTM)147.752M
  • Gross Margin (TTM)87.24%
  • Net Margin (TTM)-194.16%
  • Debt To Equity (MRQ)-44.00%

EVENTS

  • Earnings Date05/06/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On FibroGen Inc

 

Profile

MORE
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of...
James Schoeneck
Independent Chairman of the Board
Thane Wettig
Chief Executive Officer, Director, Chief Commercial Officer
Juan Graham
Chief Financial Officer
Address
409 ILLINOIS STREET
San Francisco, CA
94158
United States

Top Peers

SYMBOLLASTCHG%CHG
KPTI
Karyopharm Therapeutics Inc
1.13+0.05+4.63%
SGMO
Sangamo Therapeutics Inc
0.5558+0.0338+6.4751%
AGEN
Agenus Inc
13.07+0.55+4.39%
NSTGQ
NanoString Technologies Inc
0.205+0.0279+15.7538%
STRO
Sutro Biopharma Inc
3.83-0.11-2.79%